The U.S. District Court for the District of Columbia should vacate the 2022 outpatient prospective payment system rule insofar as it sets a payment rate for 340B hospitals that is lower than the generally applicable payment rate of Average Sales Price plus 6%, AHA told the court yesterday. 

The U.S. Supreme Court in June unanimously ruled in favor of AHA, concluding that HHS’ 2018 and 2019 reimbursement rates for 340B hospitals were unlawful, but left it to the lower court to determine the appropriate remedy. 

The Court should not give HHS “permission to continue violating the law, each and every day, for the remainder of 2022,” AHA wrote. “Here, there is only one way for the government to stop violating the law going forward because the rationale of the Supreme Court’s ruling dictates what HHS must do to fix its violation: reimburse 340B hospitals at the same rate as non-340B hospitals for the remainder of 2022.”

Headline
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…
Headline
The AHA April 23 released a blog responding to a report issued April 22 by Paragon Health Institute. The blog highlights how the report relies on a long list…
Headline
The Washington Post yesterday published a letter to the editor from AHA President and CEO Rick Pollack responding to an April 18 editorial criticizing the 340B…
Headline
The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program because “a rebate mechanism of any kind…
Headline
The AHA and others April 17 filed an amicus brief requesting the U.S. Court of Appeals for the 4th Circuit grant en banc review of a panel decision that…
Headline
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…